Phase 2 N=20 Experimental Dentifrice Remineralization/Fluoride Uptake in an in Situ Model
Dental Erosion
Primary: Percentage Surface Micro-hardness Recovery (SMHR) of Enamel Specimens — 39.46; 38.31; 36.17; 17.26 % SMHR — p=0.7756
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=24 Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
Mucosal Melanoma · Acral/Lentiginous Melanoma · Chronically Sun Damaged Melanomas
Primary: Best Overall Response — 0; 0; 0; 7 participants
Phase 1 N=63 Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Fasting Plasma Glucose (FPG) at Day 15 — 32.8; 37.9; 56.0; 2.0 mg/dL
N/A N=39 Comparative the Effect of Metformin and Acupuncture on Weight Loss and Insulin Sensitivity
Insulin Sensitivity · Obesity
Primary: Body Weight — -4.1; -1.5 kg — p=<0.001
Phase 3 N=164 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Chronic Myeloproliferative Disorders · Graft Versus Host Disease · Leukemia
Primary: Number of Patients That Develop Ocular GVHD While on Study in the Two Arms (Ocular Cyclosporine (Restasis) vs. Placebo) — 9; 8 participants — p=>0.99
Phase 4 N=24 Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects
Primary Immune Deficiency Disease
Primary: Serious Bacterial Infections. — 1; 0 Total serious bacterial infections
Phase 2 N=64 A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease · COPD
Primary: Weighted Mean (0-24hr) Change From Baseline FEV1 (Forced Expiratory Volume in 1 Second) — -14.4; 90.2; 98.5 mL
Phase 2 N=20 Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Mucosal Lentiginous Melanoma · Acral Melanoma · Melanoma
Primary: 4-month Progression-Free Survival Rate — 0.27; 0.125 proportion of patients
Phase 4 N=366 A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease
Coronary Artery Disease · Heart Disease
Primary: Number of Participants With Abnormal Contrast Stress Echocardiography and With Future Major Adverse Cardiac Events (MACE) at 2 and 5 Years Follow-Up — 2; 1; 1; 5…
Phase 2 N=72 The Effect of Reflexology on Radiation-related Fatigue in Breast Cancer Patients
Fatigue
Primary: The Lee Fatigue Scale — 3.71; 3.68; 3.9; 5.32 units on a scale
N/A N=9 Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma
Brain Tumor
Primary: Percent Decrease in Central Nervous System Bioavailability of Sulfasalazine — 17; 23; 28; 5 percentage of change
Phase 2 N=275 Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
Hepatitis C · Hepatitis C, Chronic · Nonimmune Nonviral Causes of Liver Failure
Primary: Number of Participants With Clinical Complications Usually Attributed to Immunosuppression — 12; 4 participants
Phase 3 N=283 A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
Major Depressive Disorder
Primary: Percentage of Participants With a Treatment-emergent Adverse Event (TEAE) — 78.0; 73.1; 71.1 Percentage of participants
Phase 4 N=201 Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution
Open-Angle Glaucoma · Ocular Hypertension
Primary: Least Squares Mean Change From Baseline in Intraocular Pressure (IOP) at 11 AM — 17.0; 17.0; -3.3; -3.4 mmHg
Phase 2 N=139 Effect of OC000459 on Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in Eczema Area and Severity Index (EASI) Compared to Placebo at Week 16 — -3.8; -6.1 units on a scale